La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Hansoh Pharmaceutical Group Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Huijuan Zhong

Amministratore delegato

CN¥14.8m

Compenso totale

Percentuale dello stipendio del CEO	49.6%
Mandato del CEO	8.8yrs
Proprietà del CEO	n/a
Durata media del management	8.5yrs
Durata media del Consiglio di amministrazione	6.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Huijuan Zhong rispetto agli utili di Hansoh Pharmaceutical Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	CN¥5b
Mar 31 2024	n/a	n/a	CN¥4b
Dec 31 2023	CN¥15m	CN¥7m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥11m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥16m	CN¥8m	CN¥3b

Compensazione vs Mercato: La retribuzione totale di Huijuan ($USD 2.08M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 789.58K ).

Compensazione vs guadagni: La retribuzione di Huijuan è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Huijuan Zhong (63 yo)

8.8yrs

Mandato

CN¥14,807,000

Compensazione

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	Nessun dato
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 27.9m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 25.0m
Min Hu	VP & CFO	no data	Nessun dato	Nessun dato
Chih-Hung Lee	Chief of Science Officer	2.4yrs	Nessun dato	Nessun dato
Chuanhe Xu	Senior Vice President	15.5yrs	Nessun dato	Nessun dato
Weiyong Sun	Chief Commercial Officer	no data	Nessun dato	Nessun dato
Shengli Zhong	Joint Company Secretary & Senior VP	6.1yrs	Nessun dato	Nessun dato
Sze Wai Tam	Joint Company Secretary	less than a year	Nessun dato	Nessun dato

8.5yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di 3692 è esperto e expertise (durata media dell'incarico 8.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	Nessun dato
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 27.9m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 25.0m
Guoqiang Lin	Independent Non-Executive Director	5.3yrs	CN¥360.00k	Nessun dato
Sheung Wai Chan	Independent Non-Executive Director	5.3yrs	CN¥360.00k	Nessun dato
Dongtao Yang	Independent Non-Executive Director	5.3yrs	CN¥360.00k	Nessun dato

6.9yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3692 sono considerati esperti (durata media dell'incarico 6.8 anni).

Hansoh Pharmaceutical Group Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets"

Hansoh Pharmaceutical Group Company Limited Announces That "Ibrexafungerp Tablets" Has Been Granted A Clinical Trial

Non-Executive Director Cuifang Ma has left the company

First half 2021 earnings released: EPS CN¥0.22 (vs CN¥0.21 in 1H 2020)

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Receives Approval by the National Medical Products Administration of the People ' S Republic of China for Class 1 Innovative Drug Tenofovir Amibufenamide Tablets

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ameile for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval of "Bortezomib for Injection"

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited Recommends a Final Dividend for the Year Ended December 31, 2020, Payable on July 5, 2021

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in China